https://en.wikipedia.org/wiki/Microneedles

The core challenge in drug therapy lies in maximizing therapeutic efficacy while minimizing systemic side effects. Traditional oral administration suffers significant reduction in effectiveness due to first-pass metabolism in the liver, whereas intravenous injection, although rapid in onset, results in widespread drug distribution throughout the body, offering poor targeting to specific lesions. The emergence of microneedle therapy provides a "key" to precision medicine-enabling precise control over drug release in both spatial and temporal dimensions.

In terms of spatial precision, microneedle arrays can deliver drugs directly to specific anatomical layers. The stratum corneum, epidermis, dermis, and subcutaneous tissue each have distinct physiological functions and pathological characteristics. For instance, drugs for treating vitiligo need to act on melanocytes in the basal layer of the epidermis, while anti-aging ingredients must reach fibroblasts in the dermis. With conventional topical application, large-molecule active ingredients are nearly unable to penetrate the stratum corneum; however, microneedles can be designed with needle lengths tailored to therapeutic targets, enabling precise drug release at the desired depth. This "layer-specific targeting" capability significantly enhances drug bioavailability by several to even dozens of times.

In the field of cancer therapy, microneedles offer a particularly significant advantage in spatial targeting. The dense stroma and abnormal vascular structures within solid tumors hinder the effective penetration of systemic chemotherapy drugs. Microneedle patches loaded with chemotherapeutic agents can be directly applied to the tumor surface, with their tips penetrating into the tumor tissue to release drugs locally. In animal studies, this localized delivery method achieved drug concentrations at the tumor site more than tenfold higher than those from intravenous administration, while systemic blood drug levels were only one-tenth as high, significantly reducing systemic side effects such as nausea and hair loss.

More revolutionary is the microneedle's ability to control drug release over time. By selecting different needle materials-such as biodegradable polymers like polylactic acid, hyaluronic acid, or chitosan-the release duration can be tailored from minutes to weeks. More advanced "responsive microneedles" can detect physiological signals and autonomously adjust the drug release rate. For example, glucose-responsive microneedle patches incorporate insulin carriers modified with boronic acid; when a patient's blood glucose rises, changes in surface charge trigger carrier swelling, accelerating insulin release. As glucose levels return to normal, the release rate automatically decreases. This biomimetic regulation mechanism effectively implants a miniature artificial pancreas onto the skin.

The combination of precise targeting and intelligent controlled release is ushering in a new chapter in personalized medicine. In the future, doctors will be able to tailor individual microneedle prescriptions based on patients' genotypes, metabolic rates, and disease progression. Each microneedle acts as a silent yet faithful "messenger," delivering medication accurately and reliably to its intended destination.